Pluri Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PLUR research report →
Range $12 – $12
Price Chart
About the company
Pluri Inc. , a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders.
- CEO
- Yaacov Yanay
- IPO
- 2003
- Employees
- 127
- HQ
- Haifa, HA, IL
Get TickerSpark's AI analysis on PLUR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.02M
- P/E
- -0.58
- PEG
- -0.02
- P/S
- 16.70
- P/B
- -0.90
- EV/EBITDA
- -1.85
- Div Yield
- 0.00%
- Gross Margin
- 19.00%
- Op Margin
- -2412.14%
- Net Margin
- -2424.75%
- ROE
- 203.55%
- ROIC
- -117.79%
Latest fiscal year · YoY change
- Revenue
- $1.34M+309.8%
- Gross Profit
- $654.00K+103.1%
- Op Income
- $-22,176,000
- Net Income
- $-22,583,000-8.1%
- EPS
- $-3.56+10.8%
- OCF Growth
- -1.1%
- FCF Growth
- -8.1%
- 52W High
- $5.68
- 52W Low
- $1.45
- 50D MA
- $1.89
- 200D MA
- $2.95
- Beta
- 0.67
- RSI (14)
- 45
- Avg Volume
- 26.27K
No earnings-call transcripts are available for PLUR yet.
- Free Float
- 57.2%
- Shares Outstanding
- 10.79M
- Float Shares
- 6.17M
of shares held by institutions
14 13F filers
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 1 ETFs
Biggest fund positions in PLUR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 19, 26 | SHORRER DORON | other | 0 |
| Jun 19, 26 | SHORRER DORON | other | 0 |
| Jun 30, 26 | Manieu Alexandre Weinstein | other | 641 |
| Jun 30, 26 | Manieu Alexandre Weinstein | other | 625,000 |
| Apr 21, 26 | Manieu Alexandre Weinstein | other | 312,500 |
| Apr 21, 26 | Manieu Alexandre Weinstein | other | 312,500 |
| Mar 31, 26 | Manieu Alexandre Weinstein | other | 312,500 |
| Mar 31, 26 | Manieu Alexandre Weinstein | other | 312,500 |
| Dec 8, 25 | Manieu Alexandre Weinstein | other | 625,000 |
| Dec 8, 25 | Manieu Alexandre Weinstein | other | 625,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PLUR coverage
Recent articles, reports, and earnings notes.
No research on PLUR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PLUR report →Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment
globenewswire.com · Aug 17
Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK
globenewswire.com · Jul 28
Plurilock Announces Results of Annual General Meeting
newsfilecorp.com · Jun 16
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
globenewswire.com · Jun 2
Pluri Inc. (NASDAQ:PLUR) Sees Large Increase in Short Interest
defenseworld.net · Feb 17
Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
globenewswire.com · Dec 22
Pluri (NASDAQ:PLUR) Stock Price Down 12.7% – Here’s Why
defenseworld.net · Dec 12
Plurilock Security Inc. (PLUR:CA) Q3 2025 Earnings Call Transcript
seekingalpha.com · Nov 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.